Medtronic Ventor Technologies Faces Asset Seizure Over $1.8 Billion Tax Dispute in Israel

Recently, Medtronic's Israeli subsidiary, Medtronic Ventor Technologies, encountered a major tax crisis. The Israel Tax Authority initiated enforcement proceedings and seized assets due to the company's alleged failure to pay 674 million shekels (approximately $180 million, RMB equivalent).1.3 billion yuan`)` The huge tax payment, this incident has triggered widespread attention in the industry.

It is understood that the origin of this tax dispute can be traced back to Medtronic's acquisition of Ventor Technologies, an Israeli heart valve development company, in 2009. At that time, the two parties had already disagreed on whether capital gains tax should be paid for the transfer of intellectual property rights during the acquisition process.

According to reports, in June 2023, the Lod Central District Court in Israel ruled in favor of the Tax Authority's position. The court determined that when Ventor was acquired, it transferred intellectual property rights, including 180 patents, which should be taxed separately and were unrelated to the $325 million equity transaction at that time. The court pointed out that Ventor not only granted its parent company, Medtronic, the right to use its intellectual property but also directly registered some patents under the parent company’s name without providing a convincing explanation. This action constituted "the depletion of the company's assets," thus subjecting it to substantial capital gains tax.

Data shows that Ventor Technologies, established in 2004, became a representative of Israel's medical innovation by developing a transcatheter heart valve replacement product for treating aortic diseases. Medtronic acquired 8% of its shares in 2008 and purchased the entire company the following year at a valuation of $325 million.

After the transaction was completed, Ventor became Medtronic's R&D center in Israel and signed a series of intra-group agreements with Medtronic’s headquarters and its Irish subsidiary, including providing R&D services at cost-plus and licensing intellectual property. Ventor ceased operations in 2012, but its IP continued to generate licensing revenue. However, the Israel Tax Authority argued that these arrangements masked the substance of the transaction—Ventor’s intellectual property and business had been entirely divested in the deal and should have been subject to capital gains tax at the time of the initial transaction in 2008.

Facing a hefty tax recovery claim, Ventor recently filed a petition with Israel's Supreme Court, stating that its current assets amount to less than 5% of the payable tax, and requested the court to suspend enforcement. It was also revealed that its parent company, Medtronic, had initially planned to pay approximately 40% of the tax upfront, with the remainder to be repaid over six years, reaching a preliminary draft agreement. However, just before the Jewish holiday of Passover, negotiations collapsed due to the prosecution's demand for Ventor to accept a "full settlement plan," which the company ultimately refused, prompting the tax authority to immediately initiate seizure procedures. To date, the tax authority has not responded to the Supreme Court petition.

This incident not only concerns the fate of Medtronic and its subsidiaries but has also triggered a chain reaction within the industry. Some analysts believe that Medtronic may ultimately need to pay 800–900 million shekels in taxes, accounting for approximately 80% of the original acquisition price. Such a high potential tax burden has raised concerns among many multinational corporations and Israeli domestic startups.

Oren Biran, head of the tax department at GKH Law Firm, stated that in recent years, the tax authorities have quickly launched tax audits after foreign investments in mergers and acquisitions of Israeli technology companies. Once signs of a "change in business model" are detected (such as employee transfers, IP licensing, distribution adjustments, etc.), a high tax assessment may be issued. "International manufacturers are already highly alert to this trend, and such tax issues have become an important topic during the M&A negotiation phase, potentially even affecting the final acquisition valuation."

According to public information, Medtronic's business presence in Israel has a long history, with its Israeli office established as early as 1974. In recent years, through a series of strategic acquisitions, Medtronic has continuously strengthened and expanded its position in the Israeli and global medical device markets.

In 2018, Medtronic made a significant acquisition of the Israeli orthopedic robotics company Mazor Robotics for $1.64 billion, marking a landmark event in the medical technology field. Mazor Robotics, a global leader in manufacturing robotic guidance systems for spinal surgery, revolutionized spinal procedures with its core product, the Mazor X surgical platform.

Medtronic's acquisition this time is not a simple capital operation, but a long-term strategic layout. By integrating the technological advantages of Mazor Robotics, Medtronic has quickly established an absolute leading position in the field of spinal surgery robotics. Since then, Medtronic has continuously deepened its integration with Mazor Robotics, promoting technological upgrades and product iterations.

In November 2024, Medtronic made another move by acquiring Fortimedix Surgical, a joint manufacturer. This Israeli company focuses on developing proprietary joint instrument technology applicable to endoscopic therapeutic interventions and minimally invasive surgeries. This move by Medtronic is seen as an important step in further expanding its business scope and enhancing the functionality of its surgical robot products, potentially creating a new growth point for it in the medical device field.

Notably, after Medtronic introduced Mazor X to the Chinese market, it quickly initiated localized research and production. By integrating the clinical needs of the Chinese market with Medtronic's global technological advantages, the team conducted in-depth optimization and improvements on Mazor X. Ultimately, the China-produced spinal robot, Mazor™ XC, was successfully launched. This product not only incorporates artificial intelligence technology, providing preoperative decision support and outcome simulation, but also covers the entire process of spinal surgeries, including decompression, fusion, and fixation, making it a leading choice for spinal surgeries in the Chinese market.

Notably, Medtronic has been making significant moves recently, with major actions in business spin-offs, financial performance releases, and strategic adjustments.

Recently, Medtronic announced a significant strategic decision – to spin off its diabetes business into an independent company within the next 18 months and achieve the spin-off listing through an Initial Public Offering (IPO). Medtronic's diabetes business holds a prominent position in the industry, featuring advanced technology and extensive market coverage. However, to further optimize its business portfolio, focus on high-return segments, and fully unlock the potential of the diabetes business, the company has made this decision to proceed with the spin-off.

The newly spun-off company will take over all assets of Medtronic's diabetes business, including a rich product portfolio, cutting-edge R&D pipeline, key intellectual property, global production facilities, and approximately 8,000 professional employees. Que Dallara, the current president of the diabetes business, will become the CEO of the new company, leading it on its path to independent development. Medtronic stated that the separated diabetes business will have greater autonomy and flexibility, enabling it to respond more quickly to market demands and accelerate the launch of innovative products.

In terms of performance, Medtronic announced its financial results for the fourth quarter and full year of fiscal 2025. The data showed that the full-year revenue reached 33.5 billion U.S. dollars, increasing by 3.6% year-on-year (organic growth of 4.9%), demonstrating a strong growth momentum. The net profit attributable to shareholders for the whole year was approximately 4.66 billion U.S. dollars, with GAAP diluted earnings per share of 3.61 U.S. dollars, a significant increase of 31% year-on-year, indicating a substantial improvement in profitability.

However, Medtronic also mentioned potential challenges when looking ahead to the fiscal year 2026. The company anticipates facing cost impacts from changes in tariff policies, which could add a net pressure of $200 million to $350 million to the company's cost of goods sold in fiscal year 2026. To address this challenge, Medtronic is actively taking measures to mitigate the impact of tariff costs by optimizing the supply chain and improving operational efficiency.

In addition, in response to market changes and competitive pressures, Medtronic has clarified a series of strategic adjustment directions. In terms of business layout, after spinning off its diabetes business, it will focus more on high-profit growth areas such as cardiac devices. For example, innovative products like pulsed field ablation, in which the company continues to invest in R&D, are expected to become important drivers of future performance growth.

At the same time, Medtronic deeply understands the importance of innovation for enterprise development and will continue to increase R&D investment to maintain its leading position in technology. By continuously launching innovative and competitive products, it meets clinical needs and improves patient treatment outcomes.

——

In fact, Medtronic's recent series of actions at the business, financial, and strategic levels not only demonstrate its determination and flexibility in responding to market changes but also lay a solid foundation for future development.

This tax dispute undoubtedly casts a shadow over Medtronic's business in Israel. How Medtronic will address the tax issues in the future, and whether its business layout in Israel will undergo further adjustments as a result, remain to be seen. We will continue to monitor the situation.